About US
Contact us
-
US FDA grants priority review for AstraZeneca's ovarian cancer drug olaparibThe US Food and Drug Administration (FDA) has granted priority review for AstraZeneca's new drug application (NDA) of olaparib for treatment of ovarian cancer. Olaparib is an oral poly ADP-ribose pol2014/5/4
-
Novozymes' Half-Life Extension Technology Reaches Landmark Milestone as GSK's Albiglutide is Granted FDA Marketing ApprovalFDA has granted marketing approval to GlaxoSmithKline's new Type 2 diabetes drug, branded Tanzeum in the US and Eperzan in Europe, which uses Novozymes' Veltis technology to achieve an extended half-l2014/4/30
-
Janssen's type 2 diabetes drug Vokanamet gets European Commission approval in EUJanssen-Cilag International (Janssen) has received approval from the European Commission (EC) for use of Vokanamet in the European Union (EU) as a treatment for adults with type 2 diabetes mellitus to2014/4/30
-
Boehringer gets EMA positive opinion for Pradaxa to treat DVT and PEBoehringer Ingelheim has received positive opinion from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) recommending approval of Pradaxa (dabigatran etexilate) for2014/4/29
-
NICE recommends afatinib for treatment of lung cancerThe National Institute for Health and Care Excellence (NICE) in the UK has issued its final health technology appraisal recommending afatinib as a first-line treatment option for patients with advance2014/4/29
-
Apricus's erectile dysfunction drug Vitaros gets national phase approval in SpainUS-based pharmaceutical firm Apricus Biosciences has received national phase approval from the Spanish Agency for Medicines and Health Products (AEMPS) for Vitaros, a topical on-demand treatment for e2014/4/28
-
FDA approves Janssen’s Sylvant to treat multicentric Castleman's diseaseThe US Food and Drug Administration has approved Janssen Biotech's Sylvant (siltuximab) to treat patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negativ2014/4/28
-
2014 PhexTour （Pharma Excipients Technical Application National Tour Seminar) 2nd station--Jinhua was successfully concluded2014 PhexTour （Pharma Excipients Technical Application National Tour Seminar)2nd station--Jinhua, was successfully concluded on 15April atHemei JinpanHotel.More than100 technical persons from 28 pharm2014/4/25
-
Eli Lilly's Cyramza becomes first FDA-approved gastric cancer drugEli Lilly has obtained US Food and Drug Administration approval for its Cyramza (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal ju2014/4/25
-
FDA grants orphan drug status to Bayer's bronchiectasis medicine Ciprofloxacin DPIThe US Food and Drug Administration (FDA) has granted orphan drug designation for Bayer HealthCare's investigational Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) to treat patients with2014/4/25